A core focus is the development of our own clinical-stage RNA therapeutics, having developed a broad pipeline of product candidates.

Our technology also serves as an important foundation for several external siRNA programmes currently in clinical development worldwide. We have partnerships and licenses with pharmaceutical companies around the world, demonstrating the significance of our RNA technology within the sector.

Atu027 Pancreatic Cancer report

Licensees of our siRNA trigger (AtuRNAi)

Quark Pharmaceuticals inc. (‘Quark’) has licensed Silence’s AtuRNAi® for its PF-655 product, which has in turn been licensed to Pfizer. Phase 2 results are awaited in Diabetic Macular Edema.

Novartis has taken an option to licencse Quark’s QPI 1002, targeting Delayed Graft Function (DGF) in kidney transplant patients and Acute Kidney Injury(AKI).

In October 2015 Quark’s parent company SBI Holdings reported plans to begin patient dosing in Phase 3 dosing in DGF and in Phase 2 for AKI. Both of Quark’s drugs use naked siRNA.

Click here for information on our pre-clinical development programmes.

Development of Atu027: An RNAi therapeutic for Oncology

Atu027 is a drug candidate that uses our AtuPLEX® and AtuRNAi® technologies to target the expression of the protein PKN3.

It is composed of AtuRNAi® siRNA (targeting PKN3) within a liposomal formulation – our proprietary AtuPLEX® delivery system. This transports Atu027 into the patient’s bloodstream and delivers RNAi of the target gene PKN3 in the vascular endothelium.  AtuRNAi® is one of the most thoroughly tested RNAi therapeutics in humans and has an excellent safety record, with over 400 people dosed so far and no immune response observed.